

Date: 14 November 2025

To.

Corporate Relationship Department, BSE Limited PJ Towers, Dalal Street, Mumbai 400001, MH

**Stock Code: 542248** 

**Subject: Press Release** 

Dear Sir/Madam.

Further to our previous letter for the Un-Audited Standalone and Consolidated Financial Results of the Company for the quarter ended 30 September 2025, we are enclosing a copy of the Press Release for your records.

The above information is being hosted on the Company's website <u>www.deccanhealthcare.co.in</u> in terms of Regulation 46 of the Listing Regulations, as amended.

We request you to kindly take the same on records.

Thanking You,
For and on behalf of
Deccan Health Care Limited

Ronak Darji Company Secretary & Compliance Officer

Encl: A/a

Registered Office: 6-3-347/17/5/A/Back Position, Dwarakapuri Colony, Punjagutta, Hyderabad – 500082, Telangana, India Email: info@deccanhealthcare.co.in

Tel: +91 40 4709 6427

Innovation Hub & Manufacturing: Plot No.13, Sector 03, IIE Pant Nagar, SIDCUL, Udham Singh Nagar – 263153, Uttarakhand, India CIN: L72200TG1996PLC024351

www.deccanhealthcare.co.in



# <u>DECCAN HEALTH CARE LIMITED ANNOUNCES STRONG FINANCIAL</u> <u>PERFORMANCE FOR Q2 & H1 FY 2025–26</u>

## **Sustained Growth Momentum with Expanding Market Reach and Strengthened Profitability**

#### 14th November 2025:

Deccan Health Care Limited (DHCL) has reported a robust operational and financial performance for the **quarter and half-year ended 30 September 2025**, demonstrating the company's robust revenue growth trajectory, healthy profitability and strategic focus on innovation-led, preventive healthcare solutions.

#### **Financial Performance Overview**

The company delivered significant operational performance across key metrics, showing clear momentum driven by strong product innovation acceptance, product lines expansion, and operational efficiency.

- Revenue from Operations:
  - o Standalone:
    - Quarter Performance: ₹2,440.46 lakh ↑ Growth: +29.7% YoY
    - Half-Year Performance: ₹4,587.41 lakh ↑ Growth: +35.4% YoY
  - o Consolidated:
    - Quarter Performance: ₹2,139.56 lakh
       Half-Year Performance: ₹4,353.58 lakh
- Net Profit:
  - o Standalone:
  - o Consolidated:
    - Quarterly PAT: ₹91.40 lakh
      Half-Year PAT: ₹115.11 lakh
- EPS steady and improving, signalling value accretion
- Equity Base Strengthened through share conversions
- Zero investor complaints strong governance

The results reflect a company in strong forward momentum, driven by strengthening fundamentals, expanding market reach, and rising profitability. Deccan Health Care Ltd. continues to create long-term value for its shareholders through consistent growth, operational discipline, and a steadfast focus on innovation.



In line with its strategic plan, DHCL has broadened its wellness portfolio with innovative launches such as EnergyDecc<sup>TM</sup>, SlimDecc<sup>TM</sup>, Reactive Go Advanced, and a new range of functional fruit bars and gummies. The company has also introduced its pioneering Weight Wellness Program—an integrated, science-backed approach to achieving and maintaining an ideal body weight with sustained energy, strength, and balance. Unlike conventional short-term weight loss methods, this program focuses on metabolic balance, vitality, and holistic well-being through three synergistic formulations. Together, these innovations empower individuals to "Shape and Energize the Body Naturally"—without crash diets, stimulants, or side effects.

Alongside its domestic growth, DHCL continues to expand its global footprint, with regulatory filings completed in six international markets and product launches in the UAE and GCC planned for March 2026.

**Commenting on the performance,** Mr Mohak from Deccan Health Care said: "Our Q2 performance demonstrates the resilience of our model and rising consumer preference for preventive, scientific wellness. We remain focused on disciplined execution, export-readiness, and sustained long-term value creation."

### For Media & Investor Enquiries: INFO@DECCANHEALTHCARE.CO.IN

Safe Harbour Statement:

Statements in this release relating to future performance are forward-looking and subject to risks and uncertainties that could cause actual results to differ materially, including economic conditions, regulatory approvals, competitive dynamics, supply chain disruptions, and market shifts.